MX2020004418A - Peptido derivado de koc1 y vacuna que lo incluye. - Google Patents

Peptido derivado de koc1 y vacuna que lo incluye.

Info

Publication number
MX2020004418A
MX2020004418A MX2020004418A MX2020004418A MX2020004418A MX 2020004418 A MX2020004418 A MX 2020004418A MX 2020004418 A MX2020004418 A MX 2020004418A MX 2020004418 A MX2020004418 A MX 2020004418A MX 2020004418 A MX2020004418 A MX 2020004418A
Authority
MX
Mexico
Prior art keywords
peptide
present
provides
koc1
cytotoxic
Prior art date
Application number
MX2020004418A
Other languages
English (en)
Inventor
Takuya Tsunoda
Sachiko Yamashita
Tomohisa Watanabe
Tetsuro Hikichi
Ryuji Osawa
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2020004418A publication Critical patent/MX2020004418A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)

Abstract

La presente invención provee péptidos de epítopo derivados de KOC1 que tienen la capacidad de inducir células T citotóxicas. La presente invención provee, además, polinucleótidos que codifican el péptido, células presentadoras de antígeno que presentan el péptido y células T citotóxicas que hacen blanco en el péptido, y también métodos de inducción de las células presentadoras de antígeno o CTL. La presente invención también provee composiciones y composiciones farmacéuticas que los contienen como ingrediente activo. Además, la presente invención provee métodos de tratamiento o prevención del cáncer o prevención de la recurrencia postoperatoria del mismo, usando los péptidos, polinucleótidos, células presentadoras de antígeno, células T citotóxicas o composiciones farmacéuticas de la presente invención. También se proveen métodos de inducción de una respuesta inmune contra el cáncer.
MX2020004418A 2014-08-04 2017-02-03 Peptido derivado de koc1 y vacuna que lo incluye. MX2020004418A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014158920 2014-08-04
JP2014158921 2014-08-04
JP2014158919 2014-08-04

Publications (1)

Publication Number Publication Date
MX2020004418A true MX2020004418A (es) 2020-08-06

Family

ID=55263772

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017001649A MX2017001649A (es) 2014-08-04 2015-07-31 Peptido derivado de koc1 y vacuna que lo incluye.
MX2020011561A MX2020011561A (es) 2014-08-04 2017-02-03 Peptido derivado de koc1 y vacuna que lo incluye.
MX2020004418A MX2020004418A (es) 2014-08-04 2017-02-03 Peptido derivado de koc1 y vacuna que lo incluye.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017001649A MX2017001649A (es) 2014-08-04 2015-07-31 Peptido derivado de koc1 y vacuna que lo incluye.
MX2020011561A MX2020011561A (es) 2014-08-04 2017-02-03 Peptido derivado de koc1 y vacuna que lo incluye.

Country Status (16)

Country Link
US (2) US10576102B2 (es)
EP (4) EP3981416B1 (es)
JP (2) JP6754958B2 (es)
KR (2) KR20220155610A (es)
CN (4) CN111925431A (es)
AU (2) AU2015300256B2 (es)
BR (1) BR112017002206A2 (es)
CA (1) CA2956127A1 (es)
DK (1) DK3178838T3 (es)
ES (1) ES2753652T3 (es)
IL (3) IL250175B (es)
MX (3) MX2017001649A (es)
RU (2) RU2019126629A (es)
SG (2) SG10201900933YA (es)
TW (3) TWI754234B (es)
WO (1) WO2016021506A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943978B1 (ko) * 2017-12-28 2019-01-30 주식회사 하이센스바이오 신규한 펩타이드
TW202023581A (zh) * 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN112105724A (zh) * 2018-08-09 2020-12-18 深圳华大生命科学研究院 无内源hla基因背景的抗原递呈细胞系的构建方法、抗原递呈细胞系及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6255055B1 (en) * 1998-03-09 2001-07-03 Wisconsin Alumni Research Foundation c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US20030236209A1 (en) 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
ID27788A (id) 1998-06-25 2001-04-26 Kyogo Itoh Cs Peptida-peptida antigen tumor yang diperoleh dari siklofilin b
AU2001279581A1 (en) * 2000-09-06 2002-03-22 Friederike Muller Medicament comprising a dna sequence, which codes for the rna-binding koc protein, and comprising a koc protein or dna sequence of the koc promoter
JP4608184B2 (ja) 2001-03-14 2011-01-05 ダコ デンマーク アクティーゼルスカブ 新規なｍｈｃ分子構築物、ならびに診断および処置のためにこれらの構築物を用いる方法、ならびにｍｈｃ分子の使用
JP2004000216A (ja) * 2002-04-26 2004-01-08 Kyogo Ito 腫瘍抗原
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
TW200600785A (en) 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
WO2006090810A2 (en) 2005-02-25 2006-08-31 Oncotherapy Science, Inc. Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
EP1907581A2 (en) 2005-07-27 2008-04-09 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
WO2007097469A1 (en) 2006-02-24 2007-08-30 Oncotherapy Science, Inc. A dominant negative peptide of imp-3, polynucleotide encoding the same, pharmaceutical composition containing the same, and methods for treating or preventing cancer
JP5114403B2 (ja) 2006-07-11 2013-01-09 株式会社グリーンペプタイド Ｈｌａ−ａ３スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なｓａｒｔ３由来ペプチド
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
JP5505943B2 (ja) 2011-12-27 2014-05-28 サミー株式会社 スロットマシン
JP5505945B2 (ja) 2011-12-27 2014-05-28 サミー株式会社 スロットマシン
JP5505944B2 (ja) 2011-12-27 2014-05-28 サミー株式会社 スロットマシン
TWI627182B (zh) 2013-05-24 2018-06-21 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗

Also Published As

Publication number Publication date
SG11201700836TA (en) 2017-03-30
EP3981416A2 (en) 2022-04-13
US20200155596A1 (en) 2020-05-21
CN111925413A (zh) 2020-11-13
JPWO2016021506A1 (ja) 2017-05-18
RU2699542C2 (ru) 2019-09-06
KR102489834B1 (ko) 2023-01-19
KR20220155610A (ko) 2022-11-23
CN106715461A (zh) 2017-05-24
AU2020202435A1 (en) 2020-05-07
BR112017002206A2 (pt) 2017-11-21
EP3178838A4 (en) 2018-04-25
EP4353321A2 (en) 2024-04-17
TW202024122A (zh) 2020-07-01
EP3178838A1 (en) 2017-06-14
US10576102B2 (en) 2020-03-03
TWI754234B (zh) 2022-02-01
EP3590954A3 (en) 2020-03-25
AU2015300256B2 (en) 2020-01-30
CN111925431A (zh) 2020-11-13
EP3178838B1 (en) 2019-09-18
IL287985A (en) 2022-01-01
TW202219059A (zh) 2022-05-16
CN106715461B (zh) 2020-11-24
DK3178838T3 (da) 2019-11-25
ES2753652T3 (es) 2020-04-13
IL280417A (en) 2021-03-01
IL250175B (en) 2021-02-28
AU2015300256A2 (en) 2017-03-16
AU2020202435B2 (en) 2022-05-26
JP7070945B2 (ja) 2022-05-18
MX2017001649A (es) 2017-04-27
CA2956127A1 (en) 2016-02-11
EP3590954A2 (en) 2020-01-08
CN111925414A (zh) 2020-11-13
US20170333476A1 (en) 2017-11-23
RU2019126629A (ru) 2019-10-08
TWI723958B (zh) 2021-04-11
EP3981416A3 (en) 2022-07-06
IL280417B (en) 2022-06-01
SG10201900933YA (en) 2019-02-27
MX2020011561A (es) 2020-11-24
RU2017106887A3 (es) 2019-02-21
JP2020182487A (ja) 2020-11-12
TW201619189A (zh) 2016-06-01
AU2015300256A1 (en) 2017-02-23
US11547723B2 (en) 2023-01-10
RU2017106887A (ru) 2018-09-06
JP6754958B2 (ja) 2020-09-16
WO2016021506A1 (ja) 2016-02-11
IL250175A0 (en) 2017-03-30
EP3981416B1 (en) 2024-03-20
KR20170040319A (ko) 2017-04-12

Similar Documents

Publication Publication Date Title
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2023008693A (es) Polinucleotidos moduladores.
MX2019006539A (es) Sistemas y metodos para la extraccion de productos naturales.
TW201613880A (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
MA39717A (fr) Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs
GB2541571A (en) Pharmaceutical compositions
NZ731696A (en) Method for treating cancer
IN2014MU00303A (es)
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
NZ728401A (en) High purity oritavancin and method of producing same
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
IN2014CH00840A (es)
MX2022005888A (es) Metodos para tratar afecciones oculares.
MX2018005358A (es) Comprimido de dosis alta que contiene mesalazina optimizado.
MX2020004418A (es) Peptido derivado de koc1 y vacuna que lo incluye.
MX2022006022A (es) Peptido derivado de depdc1 y vacuna que lo contiene.
MX2018004308A (es) Peptido derivado de foxm1 y vacuna que lo incluye.
NZ721832A (en) Solid forms of tenofovir
TW201613952A (en) Cdca1-derived peptide and vaccine containing same
MX2021001357A (es) Peptido derivado de cdca1 y vacuna que lo contiene.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
CR20200183A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)